Bhavana Konda
Alliance for Clinical Trials in Oncology · Ohio State University Comprehensive Cancer Center LAO · Ohio State University Comprehensive Cancer Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Bhavana Konda as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 10:17 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT06900595 · Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescents and Adults With Advanced Adrenocortical CancerNational Cancer Institute (NCI) · recruiting · Locally Advanced Adrenal Cortical Carcinoma, Metastatic Adrenal Cortical Carcinoma, Recurrent Adrenal Cortical Carcinoma · principal investigator
- Ph2NCT03914300 · Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid CancerNational Cancer Institute (NCI) · active not recruiting · Differentiated Thyroid Gland Carcinoma, Follicular Variant Thyroid Gland Papillary Carcinoma, Poorly Differentiated Thyroid Gland Carcinoma · principal investigator
- Ph2NCT01723202 · Dabrafenib With or Without Trametinib in Treating Patients With Advanced Differentiated Thyroid CancerBhavana Konda · completed · Follicular Thyroid Cancer, Insular Thyroid Cancer, Papillary Thyroid Cancer · principal investigator
- Ph2NCT00390325 · Sorafenib Tosylate in Treating Patients With Metastatic, Locally Advanced, or Recurrent Medullary Thyroid CancerNational Cancer Institute (NCI) · completed · Hereditary Thyroid Gland Medullary Carcinoma, Locally Advanced Thyroid Gland Medullary Carcinoma, Multiple Endocrine Neoplasia Type 2A · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 10:17 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Alliance for Clinical Trials in Oncology Member Site CoreU10CA180821 · NCI · ALLIANCE NCTN FOUNDATION · PI Evanthia Galanis · fiscal years 2017 to 2026Named on NCT06900595
- The Ohio State University as a Lead Academic Organization (LAO) for the Experimental Therapeutics Clinical Trials NetworkUM1CA186712 · NCI · OHIO STATE UNIVERSITY · PI SUSANNE M ARNOLD, WILLIAM E. CARSON, Narendranath Epperla · fiscal years 2017 to 2026Named on NCT03914300
- Cancer Center AdministrationP30CA016058 · NCI · OHIO STATE UNIVERSITY · PI David M Gosky · fiscal years 2016 to 2026Named on NCT00390325
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 10:17 UTC. The ranking covers the 200 most relevant of 15 PubMed records, and a shared surname and initials can bring in a namesake. All 15 on PubMed
- 447 citationsRCR 10.0
- 396 citationsRCR 26.3
- Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine Tumors.N Engl J Med · 2025148 citationsRCR 44.0
- 138 citationsRCR 11.6
- 98 citationsRCR 5.2
- Nivolumab in Metastatic Adrenocortical Carcinoma: Results of a Phase 2 Trial.J Clin Endocrinol Metab · 201991 citationsRCR 3.3
- A Randomized Study of Lenvatinib 18 mg vs 24 mg in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer.J Clin Endocrinol Metab · 202275 citationsRCR 6.6
- Different effects of KCa and KATP agonists on brain tumor permeability between syngeneic and allogeneic rat models.Brain Res · 200814 citationsRCR 0.4
- Multicenter phase 2 trial of nintedanib in advanced nonpancreatic neuroendocrine tumors.Cancer · 202012 citationsRCR 0.5
- Inhibition of Bruton's tyrosine kinase with PD-1 blockade modulates T cell activation in solid tumors.JCI Insight · 20249 citationsRCR 1.1